Search results
The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial...
14 cze 2021 · This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI.
Faecal microbiota transplantation (FMT) is the standard treatment for patients with multiple recurrent Clostridioides difficile infection (rCDI).
10 maj 2023 · The FDA has approved Seres Therapeutics and Nestlé’s SER-109, now called Vowst, for the prevention of recurrence of Clostridioides difficile infection following antibiotic treatment.
25 maj 2023 · The U.S. Food and Drug Administration (FDA) has approved VOWST™, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI).
Vowst is approved for the prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and older, following completion of antibacterial treatment for recurrent...
1 cze 2021 · These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent the official practice recommendations of the American College of Gastroenterology.
